Caligiuri, Maureen
Williams, Grace L.
Castro, Jennifer
Battalagine, Linda
Wilker, Erik
Yao, Lili
Schiller, Shawn
Toms, Angela
Li, Ping
Pardo, Eneida
Graves, Bradford
Azofeifa, Joey
Chicas, Agustin
Herbertz, Torsten
Lai, Maria
Basken, Joel
Wood, Kenneth W.
Xu, Qunli
Guichard, Sylvie M. http://orcid.org/0000-0003-1143-2805
Article History
Accepted: 30 January 2023
First Online: 24 February 2023
Declarations
:
: This study was funded by Forma Therapeutics, Inc., Watertown, MA, USA.
: Conceptualization: AC, AT, EW, GLW, JC, KWW, MC, PL, QX, SMG, SS, and TH. Data curation: BG, JA, LY, MC, and SMG. Formal analysis: BG, EW, JA, JC, LB, MC, and SMG. Investigation: AC, AT, BG, EP, EW, JB, JC, LB, LY, MC, ML, PL, SMG, and SS. Methodology: GLW, JA, JC, MC, QX, SMG, SS, and TH. Project administration: MC, SMG, PL, GLW, KWW, QX, LY, and SS. Resources: GLW, JC, LB, and LY. Software: JA. Validation: AC, EW, JC, LB, LY, SMG, and SS. Visualization: MC specifically developed the figures. TH generated de novo design visualization and authored the section describing the inception and design of FT-6876, which outlines the chemistry of intermediates and proof-of-concept molecules. JC and SMG also contributed to data visualization. Supervision: EW, GLW, LY, MC, and SMG. Writing – review and editing: All authors reviewed and approved the manuscript.
: Kenneth W. Wood and Sylvia M. Guichard declare they are employees of and hold stock in Forma Therapeutics, Inc. Maureen Caligiuri is an employee of Forma Therapeutics, Inc., and declares the provision of writing assistance, medicines, or administrative support and affirms patents (WO 2020/190792, Compositions and methods for treating AR+ forms of cancer; US 2022/0088005A, Bromodomain inhibitors for AR-driven cancers). Grace L. Williams declares having owned stock in Forma Therapeutics, Inc. within the last 36 months. Ping Li declares past employment with Forma Therapeutics, Inc. (until February 2019). Jennifer Castro was an employee of Forma Therapeutics, Inc. at the time of the study. Angela Toms declares patents as well as stock ownership generated via the normal course of employment with Forma Therapeutics, Inc. Eneida Pardo, Joel Basken, Linda Battalagine, Erik Wilker, Lili Yao, Shawn Schiller, Agustin Chicas, Maria Lai, and Bradford Graves declare no conflicts of interest within the past 36 months. Joey Azofeifa is an employee and founder of Arpeggio Bio, which was contracted by Forma Therapeutics, Inc. to undertake the PRO-Seq experiments described in this paper. Torsten Herbertz declares previous (until February 2019) employment with Forma Therapeutics Inc., stock ownership based on the conversion of incentive equity grants after an initial public offering in 2020, and patents as the inventor of FT-6876 and the related molecule FT-7051 (WO2019055877A1, WO2019055869A1, WO2020006483A1, US11,292,791, WO2020190791, US20200002332). Qunli Xu declares having owned stock in Forma Therapeutics, Inc., and a patent application assigned to Forma Therapeutics, Inc.
: All the procedures related to animal care were performed according to guidelines approved by the Institutional Animal Care and Use Committee of Pharmaron following the guidance of the Association for Assessment and Accreditation of Laboratory Animal Care.
: Not applicable due to the study being preclinical in nature.
: All data associated with this study are presented in the main text or the electronic supplementary material.
: Not applicable.